Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study

Diabetes Research and Clinical Practice

Volumn 104, Issue 1, 2014, Pages 92-96

  Díaz Soto, Gonzalo ^a   De Luis, Daniel Antonio ^a,b   Conde Vicente, Rosa ^b   Izaola Jauregui, Olatz ^b   Ramos, Carmen ^a   Romero, Enrique ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

Adipocytokines; GLP 1 analogs; Liraglutide; Type 2 diabetes; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; LEPTIN; LIRAGLUTIDE; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ADIPOKINES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84898539437     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.01.019     Document Type: Article

References (30)

1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(June (6)):1364-1379.
2. Tourrel C., Bailbé D., Meile M.J., Kergoat M., Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001, 50:1562-1570.
3. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
4. Hui H., Nourparvar A., Zhao X., Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine onophosphatedependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003, 144:1444-1455.
5. Vilsbøll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Courreges J., et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycaemic episodes in subjects with Type 2 diabetes. Diabetes Care 2007, 30:1608-1610.
6. Vilsbøll T., Brock B., Perrild H., Levin K., Lervang H.H., Kølendorf K., et al. Liraglutide, a once-daily human GLP-1 analogue improves β-cell function and arginine-stimulated insulin secretion at hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008, 25:152-156.
7. Matsuda M., Shimomura I., Sata M. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002, 277:37487-37491.
8. de Luis D.A., Gonzalez Sagrado M., Conde R., Aller R., Izaola O., Perez Castrillon J.L., et al. Relation of resistin levels with cardiovascular risk factors and insulin resistance in non-diabetes obese patients. Diab Res Clin Pract 2009, 84:174-178.
9. Matsuzawa Y. Adipocytokines and emerging therapeutic targets. Curr Atheroscler Rep 2005, 7:58-62.
10. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215.
11. Mathews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F. Homesotasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-414.
12. Lukaski H., Johson P.E. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985, 41(4):810-817.
13. Buse J.B., Rosenstock J., Sesti J., Schmidt W.E., Montanya E., Brett J.H. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
14. Jendle J., Nauck M.A., Matthews D.R., Frid A., Hermansen K., Düring M., et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009, 11(December (12)):1163-1172.
15. Sherifali D., Nerenberg K., Pullenayegum E., Cheng J.E., Gerstein H.C. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010, 33(August (8)):1859-1864.
16. Vilsbøll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Brit Med J 2012, 344(January):d7771.
17. Preumont V., Hermans M.P., Brichard S., Buysschaert M. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes Metab 2010, 36(September (4)):293-298.
18. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
19. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
20. Ellingsgaard H., Hauselmann I., Schuler B., Habib A.M., Baggio L.L., Meier D.T., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011, 17(October (11)):1481-1489.
21. Shiraki A., Oyama J., Komoda H., Asaka M., Komatsu A., Sakuma M., et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012, 221(April (2)):375-382.
22. Derosa G., Putignano P., Bossi A.C., Bonaventura A., Querci F., Franzetti I.G., et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011, 666(September (1-3)):251-256.
23. Bunck M.C., Diamant M., Eliasson B., Cornér A., Shaginian R.M., Heine R.J., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010, 33(August (8)):1734-1737.
24. Courrèges J.P., Vilsbøll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008, 25(September (9)):1129-1131.
25. Chaudhuri A., Ghanim H., Vora M., Sia C.L., Korzeniewski K., Dhindsa S., et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012, 97(January (1)):198-207.
26. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8(December (12)):728-742.
27. Christiansen T., Paulsen S.K., Bruun J.M., Ploug T., Pedersen S.B., Richelsen B. Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab 2010, 95(February (2)):911-919.
28. Li L., Miao Z., Liu R., Yang M., Liu H., Yang G. Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med 2011, 17(11-12):1168-1178.
29. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55(December (12)):3387-3393.
30. Bala M., Martin J., Kopp A., Hanses F., Buechler C., Schäffler A. In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-likepeptide-1 (GLP-1). J Clin Endocrinol Metab 2011, 96(August (8)):2493-2501.